Generate Biomedicines Long Term Debt

Generate Biomedicines posts a long-term debt of $51M as of March 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Long-Term Debt is one piece of Generate Biomedicines's financial statement story. At $51M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GENB's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Generate Biomedicines's other metric pages and overview cover the third.